Celanese Q3 Earnings Surpass Estimates Amid Lower Sales Volumes

Celanese (CE) reported Q3 adjusted EPS of $1.34, surpassing consensus estimates despite a 44% year-over-year decline, while revenue decreased 8.6% to $2.42 billion, missing expectations due to lower volumes across its Engineered Materials and Acetyl Chain segments. The company projects Q4 adjusted EPS between $0.85 and $1.00, anticipating seasonal volume declines partially offset by cost reductions, and reaffirmed its 2025 free cash flow target of $700-$800 million, prioritizing deleveraging and cost improvements. Shares have underperformed significantly, declining 57.4% over the past year.

Analysis

Celanese (CE) reported mixed Q3 2025 results, with adjusted EPS of $1.34 beating the Zacks Consensus Estimate of $1.27, despite a 44.4% year-over-year decline. Revenue fell 8.6% to $2.419 billion, missing consensus, driven by volume declines of 8% in Engineered Materials and 4% in Acetyl Chain. The company also posted a significant GAAP loss of $12.39 per share from continuing operations.

Segmental performance was varied; Engineered Materials net sales beat estimates but incurred a substantial operating loss, while Acetyl Chain net sales missed estimates. Despite operational headwinds, Celanese demonstrated financial discipline by reducing long-term debt by 8.1% sequentially to $11,655 million and generating $375 million in free cash flow, supporting its deleveraging strategy.

For Q4, Celanese projects adjusted EPS between $0.85 and $1.00, anticipating seasonal volume declines partially offset by cost reductions. Management reaffirmed its 2025 free cash flow target of $700-$800 million. However, CE shares have significantly underperformed, losing 57.4% over the past year compared to a 12.3% industry decline, and currently carry a Zacks Rank #4 (Sell).

Key Decisions for Investors

• Investors should closely monitor Celanese's ability to stabilize volume trends and improve profitability given the significant GAAP loss and continued revenue decline, despite beating adjusted EPS estimates.
• Assess the company's progress on its deleveraging strategy, supported by strong Q3 free cash flow generation and sequential debt reduction, against the reaffirmed 2025 FCF target of $700-$800 million.
• Consider the implications of the lower Q4 EPS guidance and the stock's substantial underperformance relative to the industry, which, combined with a Zacks #4 (Sell) rank, suggests ongoing near-term headwinds.